APO Research
Talk to an analyst

APO RESEARCH · REPORT

Metastatic Melanoma Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Metastatic Melanoma Drug Market Outlook and Growth Opportunities 2026

26 December 2025198 pages

Choose your research edition.

Industry ResearchMetastatic Melanoma Drug Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Metastatic Melanoma Drug Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Metastatic Melanoma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Metastatic Melanoma Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Metastatic Melanoma Drug Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Metastatic Melanoma Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Metastatic Melanoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Metastatic Melanoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Metastatic Melanoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Metastatic Melanoma Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Metastatic Melanoma Drug market include Novartis AG, Merck & Co., Inc., Pfizer Inc., Plexxikon Inc., Philogen S.p.A., Pharmis Biofarmaceutica, Lda., Ono Pharmaceutical Co., Ltd., OncoSec Medical Inc. and Oncolytics Biotech Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Metastatic Melanoma Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Metastatic Melanoma Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Metastatic Melanoma Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Metastatic Melanoma Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Metastatic Melanoma Drug Segment by Company

Novartis AG

Merck & Co., Inc.

Pfizer Inc.

Plexxikon Inc.

Philogen S.p.A.

Pharmis Biofarmaceutica, Lda.

Ono Pharmaceutical Co., Ltd.

OncoSec Medical Inc.

Oncolytics Biotech Inc.

Omeros Corporation

NewLink Genetics Corporation

Morphotek, Inc.

Millennium Pharmaceuticals, Inc.

Merck KGaA

Metastatic Melanoma Drug Segment by Type

AGI-134

ALT-801

ALT-803

AMG-232

Others

Metastatic Melanoma Drug Segment by Application

Hospital

Clinic

Others

Metastatic Melanoma Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Metastatic Melanoma Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Metastatic Melanoma Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Metastatic Melanoma Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Metastatic Melanoma Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metastatic Melanoma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Metastatic Melanoma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metastatic Melanoma Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Metastatic Melanoma Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Metastatic Melanoma Drug industry.

Chapter 3: Detailed analysis of Metastatic Melanoma Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Metastatic Melanoma Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Metastatic Melanoma Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Metastatic Melanoma Drug Industry Trends Table 2. Metastatic Melanoma Drug Industry Drivers Table 3. Metastatic Melanoma Drug Industry Opportunities and Challenges Table 4. Metastatic Melanoma Drug Industry Restraints Table 5. Global Metastatic Melanoma Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Metastatic Melanoma Drug Revenue Share by Company (2021-2026) Table 7. Global Metastatic Melanoma Drug Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Metastatic Melanoma Drug Sales Volume Share by Company (2021-2026) Table 9. Global Metastatic Melanoma Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Metastatic Melanoma Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Metastatic Melanoma Drug Key Company Manufacturing Base & Headquarters Table 12. Global Metastatic Melanoma Drug Company, Product Type & Application Table 13. Global Metastatic Melanoma Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Metastatic Melanoma Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of AGI-134 Table 18. Significant Companies of ALT-801 Table 19. Significant Companies of ALT-803 Table 20. Significant Companies of AMG-232 Table 21. Significant Companies of Others Table 22. Global Metastatic Melanoma Drug Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 23. Global Metastatic Melanoma Drug Sales Volume by Type (2021-2026) & (W Units) Table 24. Global Metastatic Melanoma Drug Sales Volume by Type (2027-2032) & (W Units) Table 25. Global Metastatic Melanoma Drug Sales Volume Share by Type (2021-2026) Table 26. Global Metastatic Melanoma Drug Sales Volume Share by Type (2027-2032) Table 27. Global Metastatic Melanoma Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Metastatic Melanoma Drug Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Metastatic Melanoma Drug Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Metastatic Melanoma Drug Sales Value Share by Type (2021-2026) Table 31. Global Metastatic Melanoma Drug Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Hospital Table 33. Significant Companies of Clinic Table 34. Significant Companies of Others Table 35. Global Metastatic Melanoma Drug Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 36. Global Metastatic Melanoma Drug Sales Volume by Application (2021-2026) & (W Units) Table 37. Global Metastatic Melanoma Drug Sales Volume by Application (2027-2032) & (W Units) Table 38. Global Metastatic Melanoma Drug Sales Volume Share by Application (2021-2026) Table 39. Global Metastatic Melanoma Drug Sales Volume Share by Application (2027-2032) Table 40. Global Metastatic Melanoma Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Metastatic Melanoma Drug Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Metastatic Melanoma Drug Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Metastatic Melanoma Drug Sales Value Share by Application (2021-2026) Table 44. Global Metastatic Melanoma Drug Sales Value Share by Application (2027-2032) Table 45. Global Metastatic Melanoma Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 46. Global Metastatic Melanoma Drug Sales by Region (2021-2026) & (W Units) Table 47. Global Metastatic Melanoma Drug Sales Market Share by Region (2021-2026) Table 48. Global Metastatic Melanoma Drug Sales by Region (2027-2032) & (W Units) Table 49. Global Metastatic Melanoma Drug Sales Market Share by Region (2027-2032) Table 50. Global Metastatic Melanoma Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Metastatic Melanoma Drug Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Metastatic Melanoma Drug Sales Value Share by Region (2021-2026) Table 53. Global Metastatic Melanoma Drug Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Metastatic Melanoma Drug Sales Value Share by Region (2027-2032) Table 55. Global Metastatic Melanoma Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Metastatic Melanoma Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Metastatic Melanoma Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 58. Global Metastatic Melanoma Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Metastatic Melanoma Drug Sales by Country (2021-2026) & (W Units) Table 60. Global Metastatic Melanoma Drug Sales Market Share by Country (2021-2026) Table 61. Global Metastatic Melanoma Drug Sales by Country (2027-2032) & (W Units) Table 62. Global Metastatic Melanoma Drug Sales Market Share by Country (2027-2032) Table 63. Global Metastatic Melanoma Drug Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Metastatic Melanoma Drug Sales Value Market Share by Country (2021-2026) Table 65. Global Metastatic Melanoma Drug Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Metastatic Melanoma Drug Sales Value Market Share by Country (2027-2032) Table 67. Novartis AG Company Information Table 68. Novartis AG Business Overview Table 69. Novartis AG Metastatic Melanoma Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Novartis AG Metastatic Melanoma Drug Product Portfolio Table 71. Novartis AG Recent Development Table 72. Merck & Co., Inc. Company Information Table 73. Merck & Co., Inc. Business Overview Table 74. Merck & Co., Inc. Metastatic Melanoma Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Merck & Co., Inc. Metastatic Melanoma Drug Product Portfolio Table 76. Merck & Co., Inc. Recent Development Table 77. Pfizer Inc. Company Information Table 78. Pfizer Inc. Business Overview Table 79. Pfizer Inc. Metastatic Melanoma Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Pfizer Inc. Metastatic Melanoma Drug Product Portfolio Table 81. Pfizer Inc. Recent Development Table 82. Plexxikon Inc. Company Information Table 83. Plexxikon Inc. Business Overview Table 84. Plexxikon Inc. Metastatic Melanoma Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Plexxikon Inc. Metastatic Melanoma Drug Product Portfolio Table 86. Plexxikon Inc. Recent Development Table 87. Philogen S.p.A. Company Information Table 88. Philogen S.p.A. Business Overview Table 89. Philogen S.p.A. Metastatic Melanoma Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Philogen S.p.A. Metastatic Melanoma Drug Product Portfolio Table 91. Philogen S.p.A. Recent Development Table 92. Pharmis Biofarmaceutica, Lda. Company Information Table 93. Pharmis Biofarmaceutica, Lda. Business Overview Table 94. Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Product Portfolio Table 96. Pharmis Biofarmaceutica, Lda. Recent Development Table 97. Ono Pharmaceutical Co., Ltd. Company Information Table 98. Ono Pharmaceutical Co., Ltd. Business Overview Table 99. Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Product Portfolio Table 101. Ono Pharmaceutical Co., Ltd. Recent Development Table 102. OncoSec Medical Inc. Company Information Table 103. OncoSec Medical Inc. Business Overview Table 104. OncoSec Medical Inc. Metastatic Melanoma Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. OncoSec Medical Inc. Metastatic Melanoma Drug Product Portfolio Table 106. OncoSec Medical Inc. Recent Development Table 107. Oncolytics Biotech Inc. Company Information Table 108. Oncolytics Biotech Inc. Business Overview Table 109. Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Oncolytics Biotech Inc. Metastatic Melanoma Drug Product Portfolio Table 111. Oncolytics Biotech Inc. Recent Development Table 112. Omeros Corporation Company Information Table 113. Omeros Corporation Business Overview Table 114. Omeros Corporation Metastatic Melanoma Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Omeros Corporation Metastatic Melanoma Drug Product Portfolio Table 116. Omeros Corporation Recent Development Table 117. NewLink Genetics Corporation Company Information Table 118. NewLink Genetics Corporation Business Overview Table 119. NewLink Genetics Corporation Metastatic Melanoma Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. NewLink Genetics Corporation Metastatic Melanoma Drug Product Portfolio Table 121. NewLink Genetics Corporation Recent Development Table 122. Morphotek, Inc. Company Information Table 123. Morphotek, Inc. Business Overview Table 124. Morphotek, Inc. Metastatic Melanoma Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Morphotek, Inc. Metastatic Melanoma Drug Product Portfolio Table 126. Morphotek, Inc. Recent Development Table 127. Millennium Pharmaceuticals, Inc. Company Information Table 128. Millennium Pharmaceuticals, Inc. Business Overview Table 129. Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Product Portfolio Table 131. Millennium Pharmaceuticals, Inc. Recent Development Table 132. Merck KGaA Company Information Table 133. Merck KGaA Business Overview Table 134. Merck KGaA Metastatic Melanoma Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Merck KGaA Metastatic Melanoma Drug Product Portfolio Table 136. Merck KGaA Recent Development Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Metastatic Melanoma Drug Distributors List Table 140. Metastatic Melanoma Drug Customers List Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Metastatic Melanoma Drug Product Image Figure 2. Global Metastatic Melanoma Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Metastatic Melanoma Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Metastatic Melanoma Drug Sales (2021-2032) & (W Units) Figure 5. Global Metastatic Melanoma Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Metastatic Melanoma Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. AGI-134 Image Figure 10. ALT-801 Image Figure 11. ALT-803 Image Figure 12. AMG-232 Image Figure 13. Others Image Figure 14. Global Metastatic Melanoma Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 15. Global Metastatic Melanoma Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Metastatic Melanoma Drug Sales Volume Share by Type (2021-2032) Figure 17. Global Metastatic Melanoma Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Metastatic Melanoma Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Metastatic Melanoma Drug Sales Value Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Others Image Figure 23. Global Metastatic Melanoma Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 24. Global Metastatic Melanoma Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Metastatic Melanoma Drug Sales Volume Share by Application (2021-2032) Figure 26. Global Metastatic Melanoma Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Metastatic Melanoma Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Metastatic Melanoma Drug Sales Value Share by Application (2021-2032) Figure 29. Global Metastatic Melanoma Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 30. Global Metastatic Melanoma Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Metastatic Melanoma Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Metastatic Melanoma Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Metastatic Melanoma Drug Sales Value (2021-2032) & (US$ Million) Figure 34. North America Metastatic Melanoma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Metastatic Melanoma Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Metastatic Melanoma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Metastatic Melanoma Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Metastatic Melanoma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Metastatic Melanoma Drug Sales Value (2021-2032) & (US$ Million) Figure 40. South America Metastatic Melanoma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Metastatic Melanoma Drug Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Metastatic Melanoma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Metastatic Melanoma Drug Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Metastatic Melanoma Drug Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • AGI-134
  • ALT-801
  • ALT-803
  • AMG-232
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Plexxikon Inc.
  • Philogen S.p.A.
  • Pharmis Biofarmaceutica, Lda.
  • Ono Pharmaceutical Co., Ltd.
  • OncoSec Medical Inc.
  • Oncolytics Biotech Inc.
  • Omeros Corporation
  • NewLink Genetics Corporation
  • Morphotek, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Merck KGaA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Metastatic Melanoma Drug Sales Value (2021-2032)
  4. 1.2.2 Global Metastatic Melanoma Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Metastatic Melanoma Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Metastatic Melanoma Drug Market Dynamics
  1. 2.1 Metastatic Melanoma Drug Industry Trends
  2. 2.2 Metastatic Melanoma Drug Industry Drivers
  3. 2.3 Metastatic Melanoma Drug Industry Opportunities and Challenges
  4. 2.4 Metastatic Melanoma Drug Industry Restraints
3 Metastatic Melanoma Drug Market by Company
  1. 3.1 Global Metastatic Melanoma Drug Company Revenue Ranking in 2025
  2. 3.2 Global Metastatic Melanoma Drug Revenue by Company (2021-2026)
  3. 3.3 Global Metastatic Melanoma Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Metastatic Melanoma Drug Average Price by Company (2021-2026)
  5. 3.5 Global Metastatic Melanoma Drug Company Ranking (2024-2026)
  6. 3.6 Global Metastatic Melanoma Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Metastatic Melanoma Drug Company Product Type and Application
  8. 3.8 Global Metastatic Melanoma Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Metastatic Melanoma Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Metastatic Melanoma Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Metastatic Melanoma Drug Market by Type
  1. 4.1 Metastatic Melanoma Drug Type Introduction
  2. 4.1.1 AGI-134
  3. 4.1.2 ALT-801
  4. 4.1.3 ALT-803
  5. 4.1.4 AMG-232
  6. 4.1.5 Others
  7. 4.2 Global Metastatic Melanoma Drug Sales Volume by Type
  8. 4.2.1 Global Metastatic Melanoma Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Metastatic Melanoma Drug Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Metastatic Melanoma Drug Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Metastatic Melanoma Drug Sales Value by Type
  12. 4.3.1 Global Metastatic Melanoma Drug Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Metastatic Melanoma Drug Sales Value by Type (2021-2032)
  14. 4.3.3 Global Metastatic Melanoma Drug Sales Value Share by Type (2021-2032)
5 Metastatic Melanoma Drug Market by Application
  1. 5.1 Metastatic Melanoma Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Metastatic Melanoma Drug Sales Volume by Application
  6. 5.2.1 Global Metastatic Melanoma Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Metastatic Melanoma Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Metastatic Melanoma Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Metastatic Melanoma Drug Sales Value by Application
  10. 5.3.1 Global Metastatic Melanoma Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Metastatic Melanoma Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Metastatic Melanoma Drug Sales Value Share by Application (2021-2032)
6 Metastatic Melanoma Drug Regional Sales and Value Analysis
  1. 6.1 Global Metastatic Melanoma Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Metastatic Melanoma Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Metastatic Melanoma Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Metastatic Melanoma Drug Sales by Region (2027-2032)
  5. 6.3 Global Metastatic Melanoma Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Metastatic Melanoma Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Metastatic Melanoma Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Metastatic Melanoma Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Metastatic Melanoma Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Metastatic Melanoma Drug Sales Value (2021-2032)
  12. 6.6.2 North America Metastatic Melanoma Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Metastatic Melanoma Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Metastatic Melanoma Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Metastatic Melanoma Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Metastatic Melanoma Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Metastatic Melanoma Drug Sales Value (2021-2032)
  21. 6.9.2 South America Metastatic Melanoma Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Metastatic Melanoma Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Metastatic Melanoma Drug Sales Value Share by Country, 2025 VS 2032
7 Metastatic Melanoma Drug Country-level Sales and Value Analysis
  1. 7.1 Global Metastatic Melanoma Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Metastatic Melanoma Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Metastatic Melanoma Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Metastatic Melanoma Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Metastatic Melanoma Drug Sales by Country (2027-2032)
  6. 7.4 Global Metastatic Melanoma Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Metastatic Melanoma Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Metastatic Melanoma Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Metastatic Melanoma Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Metastatic Melanoma Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Metastatic Melanoma Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Metastatic Melanoma Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Metastatic Melanoma Drug Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Merck & Co., Inc.
  8. 8.2.1 Merck & Co., Inc. Company Information
  9. 8.2.2 Merck & Co., Inc. Business Overview
  10. 8.2.3 Merck & Co., Inc. Metastatic Melanoma Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co., Inc. Metastatic Melanoma Drug Product Portfolio
  12. 8.2.5 Merck & Co., Inc. Recent Developments
  13. 8.3 Pfizer Inc.
  14. 8.3.1 Pfizer Inc. Company Information
  15. 8.3.2 Pfizer Inc. Business Overview
  16. 8.3.3 Pfizer Inc. Metastatic Melanoma Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Inc. Metastatic Melanoma Drug Product Portfolio
  18. 8.3.5 Pfizer Inc. Recent Developments
  19. 8.4 Plexxikon Inc.
  20. 8.4.1 Plexxikon Inc. Company Information
  21. 8.4.2 Plexxikon Inc. Business Overview
  22. 8.4.3 Plexxikon Inc. Metastatic Melanoma Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Plexxikon Inc. Metastatic Melanoma Drug Product Portfolio
  24. 8.4.5 Plexxikon Inc. Recent Developments
  25. 8.5 Philogen S.p.A.
  26. 8.5.1 Philogen S.p.A. Company Information
  27. 8.5.2 Philogen S.p.A. Business Overview
  28. 8.5.3 Philogen S.p.A. Metastatic Melanoma Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Philogen S.p.A. Metastatic Melanoma Drug Product Portfolio
  30. 8.5.5 Philogen S.p.A. Recent Developments
  31. 8.6 Pharmis Biofarmaceutica, Lda.
  32. 8.6.1 Pharmis Biofarmaceutica, Lda. Company Information
  33. 8.6.2 Pharmis Biofarmaceutica, Lda. Business Overview
  34. 8.6.3 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Product Portfolio
  36. 8.6.5 Pharmis Biofarmaceutica, Lda. Recent Developments
  37. 8.7 Ono Pharmaceutical Co., Ltd.
  38. 8.7.1 Ono Pharmaceutical Co., Ltd. Company Information
  39. 8.7.2 Ono Pharmaceutical Co., Ltd. Business Overview
  40. 8.7.3 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Product Portfolio
  42. 8.7.5 Ono Pharmaceutical Co., Ltd. Recent Developments
  43. 8.8 OncoSec Medical Inc.
  44. 8.8.1 OncoSec Medical Inc. Company Information
  45. 8.8.2 OncoSec Medical Inc. Business Overview
  46. 8.8.3 OncoSec Medical Inc. Metastatic Melanoma Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 OncoSec Medical Inc. Metastatic Melanoma Drug Product Portfolio
  48. 8.8.5 OncoSec Medical Inc. Recent Developments
  49. 8.9 Oncolytics Biotech Inc.
  50. 8.9.1 Oncolytics Biotech Inc. Company Information
  51. 8.9.2 Oncolytics Biotech Inc. Business Overview
  52. 8.9.3 Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Oncolytics Biotech Inc. Metastatic Melanoma Drug Product Portfolio
  54. 8.9.5 Oncolytics Biotech Inc. Recent Developments
  55. 8.10 Omeros Corporation
  56. 8.10.1 Omeros Corporation Company Information
  57. 8.10.2 Omeros Corporation Business Overview
  58. 8.10.3 Omeros Corporation Metastatic Melanoma Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Omeros Corporation Metastatic Melanoma Drug Product Portfolio
  60. 8.10.5 Omeros Corporation Recent Developments
  61. 8.11 NewLink Genetics Corporation
  62. 8.11.1 NewLink Genetics Corporation Company Information
  63. 8.11.2 NewLink Genetics Corporation Business Overview
  64. 8.11.3 NewLink Genetics Corporation Metastatic Melanoma Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 NewLink Genetics Corporation Metastatic Melanoma Drug Product Portfolio
  66. 8.11.5 NewLink Genetics Corporation Recent Developments
  67. 8.12 Morphotek, Inc.
  68. 8.12.1 Morphotek, Inc. Company Information
  69. 8.12.2 Morphotek, Inc. Business Overview
  70. 8.12.3 Morphotek, Inc. Metastatic Melanoma Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Morphotek, Inc. Metastatic Melanoma Drug Product Portfolio
  72. 8.12.5 Morphotek, Inc. Recent Developments
  73. 8.13 Millennium Pharmaceuticals, Inc.
  74. 8.13.1 Millennium Pharmaceuticals, Inc. Company Information
  75. 8.13.2 Millennium Pharmaceuticals, Inc. Business Overview
  76. 8.13.3 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Product Portfolio
  78. 8.13.5 Millennium Pharmaceuticals, Inc. Recent Developments
  79. 8.14 Merck KGaA
  80. 8.14.1 Merck KGaA Company Information
  81. 8.14.2 Merck KGaA Business Overview
  82. 8.14.3 Merck KGaA Metastatic Melanoma Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Merck KGaA Metastatic Melanoma Drug Product Portfolio
  84. 8.14.5 Merck KGaA Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Metastatic Melanoma Drug Value Chain Analysis
  2. 9.1.1 Metastatic Melanoma Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Metastatic Melanoma Drug Sales Mode & Process
  6. 9.2 Metastatic Melanoma Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Metastatic Melanoma Drug Distributors
  9. 9.2.3 Metastatic Melanoma Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst